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In recent years, considerable advances have been made in the characterization of protein-coding alterations
involved in the pathogenesis of melanoma. However, despite their growing implication in cancer, little is known
about the role of long noncoding RNAs in melanoma progression. We hypothesized that copy number
alterations (CNAs) of intergenic nonprotein-coding domains could help identify long intergenic noncoding RNAs
(lincRNAs) associated with metastatic cutaneous melanoma. Among several candidates, our approach uncovered
the chromosome 6p22.3 CASC15 (cancer susceptibility candidate 15) lincRNA locus as a frequently gained
genomic segment in metastatic melanoma tumors and cell lines. The locus was actively transcribed in metastatic
melanoma cells, and upregulation of CASC15 expression was associated with metastatic progression to brain
metastasis in a mouse xenograft model. In clinical specimens, CASC15 levels increased during melanoma
progression and were independent predictors of disease recurrence in a cohort of 141 patients with AJCC
(American Joint Committee on Cancer) stage III lymph node metastasis. Moreover, small interfering RNA (siRNA)
knockdown experiments revealed that CASC15 regulates melanoma cell phenotype switching between
proliferative and invasive states. Accordingly, CASC15 levels correlated with known gene signatures
corresponding to melanoma proliferative and invasive phenotypes. These ﬁndings support a key role for
CASC15 in metastatic melanoma.
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INTRODUCTION
In 2015, the rising incidence of cutaneous melanoma
continues to outpace most other cancers in the United States
(Siegel et al., 2015). The situation is alarming given the high
propensity of melanoma lesions to metastasize to many major
organ sites, including liver, lung, and brain. This translates
into a 5-year overall survival rate of ˂20% in patients with
AJCC (American Joint Committee on Cancer) stage IV disease
(McDermott et al., 2014). In recent years, the successful
development of new FDA (Food and Drug Administration)–
approved targeting agents such as vemurafenib/dabrafenib
(BRAFmt inhibitors), trametinib (MEK inhibitor), ipilimumab
(CTLA-4 antibody), and more recently pembrolizumab (PD-1
antibody) has signiﬁcantly improved patient survival, but
unfortunately most tumors eventually become drug resistant
and undergo lethal progression o2 years after the start of
treatment (Hodi et al., 2010; Alcala and Flaherty, 2012;
Ascierto et al., 2013; McArthur et al., 2014; Postow et al.,
2015). To overcome this issue and expand the number of
patients who could beneﬁt from targeted therapies, current
research focuses on the identiﬁcation of melanoma molecular
subtypes that could be targeted by speciﬁc inhibitor combi-
nations and/or be used as biomarkers to guide treatment
decisions (Vidwans et al., 2011). Thus far, considerable
progress has been made in the characterization of genetic
and epigenetic alterations affecting protein-coding genes and
corresponding signaling pathways (Shtivelman et al., 2014). In
contrast, aside from microRNAs, less is known about the
contribution of nonprotein-coding genes to melanoma progres-
sion. Recently, long noncoding RNAs (lncRNAs) have emerged
as important regulators of multiple biological functions in
various diseases including cancer (Kung et al., 2013).
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Traditionally considered, for the most part, as transcriptional
noise resulting from genome-wide pervasive transcription,
lncRNAs are now increasingly recognized as master regulators
of crucial cellular processes such as cell-cycle regulation
(Hung et al., 2011), cell fate and differentiation (Flynn and
Chang, 2014), p53 response (Huarte et al., 2010; Marin-Bejar
et al., 2013), and chromatin remodeling (Rinn and Chang,
2012). The number of identiﬁed lncRNAs is constantly rising:
for instance, since 2009, the number of GENCODE annotated
lncRNA transcripts has more than doubled, going from
∼10,000 to 426,000 in the most recent versions
(gencodegenes.org/stats/current.html). LncRNAs are classiﬁed
in different subgroups according to their function or their
location based on their intersection with protein-coding genes
(Derrien et al., 2012). The latter includes antisense transcripts
that share exon(s) with coding genes, sense or antisense
transcripts that overlap protein-coding exons, intronic sense/
antisense transcripts, and long intergenic (or intervening)
noncoding RNAs (lincRNAs) that are located between
protein-coding genes. LincRNAs represent the majority
of all lncRNAs (Cabili et al., 2011), and, although a growing
number are now implicated in cancer (Gutschner and
Diederichs, 2012), only a few have been characterized in
melanoma.
In this study, driven by the hypothesis that recurrent DNA
copy number alterations (CNAs) in metastatic melanoma
specimens may help identify clinically relevant lincRNAs, we
assessed the copy number status of 42,300 previously
published intergenic domains that were used to uncover
actively transcribed lincRNAs in nonmelanoma cell lines
(Khalil et al., 2009). Our approach identiﬁed the CASC15
(cancer susceptibility candidate 15) locus as a frequently
altered lincRNA domain in metastatic melanoma whose
transcript levels correlate with disease progression and
function as regulators of metastatic melanoma cell transition
between proliferative and invasive states.
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Figure 1. Copy number alterations (CNAs) of “K4-K36” intergenic domains in metastatic melanoma cell lines and tissues. (a) Circos plot depicting CNAs of
2,367 intergenic domains identiﬁed in Khalil et al. (2009). Each green (or red) dot represents the number of metastatic melanoma specimens that showed copy
number gain (or loss) of a speciﬁc domain. (b) Frequency (%) of the most recurrent CNAs as a function of chromosome arm. Top graph: frequent copy number
losses (in 430% of specimens); red bar highlights chromosome 6q alterations. Lower graph: copy number gains (in 440% of specimens); green bar highlights
chromosome 6p alterations. (c) Plot zooming of the chromosome 6p22.3–22.2 region representing copy number data for the 78 melanoma specimens
interrogated in a. Each row represents a patient.
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RESULTS
Identiﬁcation of lincRNA domains associated with metastatic
melanoma
To uncover lincRNAs involved in metastatic melanoma
progression, we assessed the copy number status of 2,367
intergenic domains in 78 metastatic melanoma samples (42
cell lines and 36 tissues; see Supplementary Table S1 online
for details). These genomic segments were previously identi-
ﬁed in nonmelanoma cell lines as putative nonprotein-coding
transcriptional units due to the presence of a histone H3 lysine
4 and H3 lysine 36 trimethylation (K4-K36) signature
indicative of active transcription (Khalil et al., 2009). We
found several CNAs associated with these domains in both
melanoma cell lines and tissues (Figure 1a and Supplementary
Tables S2 and S3 online). Most gains and losses were located
on chromosome arms frequently altered in metastatic
melanoma (Broad Institute TCGA Genome Data Analysis
Center (2014): Analysis Overview for Skin Cutaneous Mela-
noma (Metastatic cohort)—15 July 2014. Broad Institute of
MIT and Harvard. doi:10.7908/C18P5Z9Z). However, the
alteration pattern of chromosome 6 domains was particularly
striking: among the most frequently gained or deleted
segments, 34% were located on the 6p arm and 35% on the
6q arm, respectively (Figure 1b and Supplementary Tables S2
and S3 online). To identify tumor-promoting lincRNAs, we
focused downstream analyses on the most frequently gained
6p domains. We identiﬁed 18 gained regions with annotated
lincRNA transcripts, 4 of them overlapping between RefSeq
and GENCODE v17 databases (Supplementary Table S4
online). We then interrogated the TCGA (The Cancer Genome
Atlas) melanoma database (n=278) for CNAs and RNA
expression using the cBioPortal (Gao et al., 2013). We
Rhesus
PhastCons
GENECODE v17
RefSeq genes
chr. 6p22.3: 21,700,000 21,800,000 21,900,000 22,000,000 22,100,000 22,200,000 22,300,000
Mouse
Dog
Opossum
Chicken
Zebrafish
Multiz alignments of 100 vertebrates
SOX4
CASC15
CASC14
PRL
PRL
SOX4
SOX4
LINC00340
RN7SKP240
RP1-67M12.2
RP11-524C21.2
RP3-404K8.2
PRL
0
2
4
6
8
10
π
ψ
0
2
4
6
8
10
0
1
2
3
4
5
15
20
25
*
*
R
el
at
iv
e 
CA
SC
15
 
le
ve
ls
 (L
OG
2 
n
+
1) Melanocytes (n =2)
Melanoma cell lines (n =30)
Cell lines
R
el
at
iv
e 
CA
SC
15
 
le
ve
ls
(LO
G 2
 
n
+
1)
BRAFwt (9) BRAFmt (20)
Fo
ld
-c
ha
ng
e
YDFR.SB3
YDFR.C
CASC14 CASC15
Figure 2. The 6p22.3 CASC15 (cancer susceptibility candidate 15) long intergenic noncoding RNA (lincRNA) locus is actively transcribed in melanoma cell
lines. (a) The University of California Santa Cruz (UCSC) genome browser–derived representation of the CASC15 locus on chromosome 6p22.3 (GRCh37/hg19
assembly), along with RefSeq and GENCODE v17 annotated genes, PhastCons conservation levels, and Multiz Alignments. (b) Reverse transcription and
quantitative PCR (RT-qPCR) detection of CASC15 (exon 8) levels in melanocytes (gray bars, n=2; c: pMEL-NRAS; π: primary melanocytes) and melanoma cell
lines (black bars, n= 30). (LOG2 (n+1) of 2
− (ddCq) relative values). (c) CASC15 expression (RT-qPCR; exon 8) in BRAF wild-type (BRAFwt; N= 9) and BRAF mutant
(BRAFmt; N= 20) melanoma cell lines. BRAFmt includes V600E (N=16), V600K (N=3), and V600R (N=1) (LOG2 (n+1) of 2
− (ddCq) relative values; whiskers
minimum (Min) to maximum (Max); T-test, P40.05). (d) Relative CASC15 and CASC14 expression levels (RT-qPCR; exon 8) in a xenograft model of melanoma
brain metastasis. Gray bars: parental YDFR.C cell line. Black bars: brain metastasis variant YDFR.SB3 (2− (ddCq) value relative to parental cells, T-test, *Po0.05;
mean± SEM, N= 3).
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conﬁrmed that 2 of these 4 domains––i.e., CASC15 and
LOC100132354––were transcribed in melanoma specimens.
Most importantly, unlike LOC100132354, the frequent copy
number gains at the CASC15 locus were correlated with an
increment in CASC15 expression (Supplementary Figure S1
online). Intrigued by this correlation (Spearman’s rho: 0.442),
we wondered whether this could be accompanied by focal
ampliﬁcation of the locus. A closer look at the 6p22.3 region,
however, conﬁrmed that CASC15 gains are associated with
arm-level CNAs rather than focal ampliﬁcations (Figure 1c and
Supplementary Figure S2 online). Nevertheless, although
CASC15 remains barely detectable in normal human tissues
(Supplementary Figure S3a online), TCGA pan-cancer analysis
revealed that melanoma ranks third among 23 tumor types for
the highest median CASC15 expression levels (Supplementary
Figure S3b online). Altogether, these ﬁndings prompted us to
investigate the role of the CASC15 locus in melanoma.
CASC15 RNA is expressed in melanoma lines and upregulated in
a xenograft model of melanoma brain metastasis
The CASC15 intergenic locus (National Center for Biotech-
nology Information (NCBI) Gene ID: 401237), formerly
known as the LINC00340 or FLJ22536 locus, spans ~ 530 kb
between the SOX4 and PRL genes on chromosome 6p22.3
(Figure 2a and Supplementary Figure S4 online). According to
the RefSeq database (release 59), the region encodes a
predicted polyadenylated 1,900-nucleotide 12-exon CASC15
transcript on the plus strand, as well as a polyadenylated
2,300- nucleotide 3-exon CASC14 transcript on the minus
strand, between exons 9 and 10 of CASC15. The GENCODE
v17 database also includes both lincRNA genes, but CASC15
is annotated as a 327-bp transcript composed of 2 exons that
correspond to exons 8 and 9 of the RefSeq annotation.
Despite this discrepancy, the existence of multiple spliced
expressed sequence tags (ESTs) aligning with the plus strand
of the CASC15 locus indicates that multiple isoforms may be
expressed (Supplementary Figure S4 online).
We ﬁrst assessed the expression of CASC14 and CASC15
transcripts in cultured melanocytes (primary culture and
pMEL-NRAS cell line) and metastatic melanoma cell lines
by reverse transcription and quantitative PCR (RT-qPCR) using
primer pairs targeting CASC14 exon 3 and CASC15 exon 8
(conserved between RefSeq, GENCODE v17, and several
ESTs; Supplementary Figure S4 online). CASC14 was
expressed in all 30 melanoma metastasis cell lines and in
pMEL-NRAS cells but was undetected in cultured melano-
cytes (Supplementary Figure S5a online). CASC15 was
detected in both melanocyte cultures and in 28 of 30
metastatic melanoma lines (Figure 2b). Levels of both
lincRNAs were highly variable among cell lines but were
not related to the BRAF mutation status of melanoma cells
(Figure 2c and Supplementary Figure S5b online).
We then examined CASC14 and CASC15 expression levels
in a human melanoma xenograft mouse model of brain
metastasis (Izraely et al., 2012). In this model, the brain
metastasis variant cell line YDFR.SB3 was obtained from the
cutaneous variant YDFR.C. Remarkably, CASC14 and
CASC15 transcripts were signiﬁcantly upregulated 2- and
17-fold in brain metastasis YDFR.SB3 cells compared with
cutaneous YDFR.C cells, and this upregulation was accom-
panied by a single copy gain of the CASC15 locus in YDFR.
SB3 cells (Figure 2d). These observations suggest that
lincRNAs transcribed from the CASC15 locus may be
associated with melanoma metastasis progression.
RACE identiﬁes an alternative CASC15 TSS and multiple splice
variants
Given the high number of spliced ESTs associated with the
plus strand of the CASC15 locus (Supplementary Figure S4
online), and the signiﬁcant induction of CASC15 RNA in the
brain metastatic variant YDFR.SB3 (Figure 2d), we performed
5′- and 3′-RACE (rapid ampliﬁcation of complementary DNA
(cDNA) ends) to determine whether several CASC15 splice
variants were present in melanoma cell lines. Using CASC15
exon 8 as the template for nested gene-speciﬁc primers, we
screened cDNA from three metastatic melanoma cell lines
and conﬁrmed the existence of several CASC15 isoforms
(Figure 3a and Supplementary Table S5 online). Interestingly,
we also identiﬁed an alternative transcriptional start site (TSS)
located between exons 4 and 5 of the predicted RefSeq
sequence (exon 1b; Figure 3a and Supplementary Table S5
online). These ﬁrst exon variants aligned with known EST- and
CaptureSeq-derived sequences (Supplementary Figure S4
online; Mercer et al., 2012). We assessed the protein-coding
potential of the cloned isoforms using the CPAT algorithm
(Wang et al., 2013) and found that all sequences had low
coding capacity similar to the annotated sequences
(Supplementary Table S5 online). In addition, scanning the
putative full-length CASC15 isoform sequences against the
Pfam database (Finn et al., 2014) did not retrieve any
catalogued protein family domains.
We then assessed the expression levels of different groups
of isoforms by RT-qPCR and observed strong positive
correlations between each cloned variants (Supplementary
Figure S6 online). On average, absolute quantiﬁcation
revealed that isoforms downstream of the alternative TSS
were expressed at 0.35 copies per cell (or 15 ng of total RNA;
Figure 3b). In contrast, RefSeq-annotated exons 1–2 and 4–5
located upstream of the alternative TSS were barely detect-
able (o0.01 copy). This ﬁnding supports 5′-RACE cloning
results and suggests an important role of the alternative TSS in
melanoma cells. We also analyzed the subcellular localiza-
tion (cytoplasm vs. nucleus) of the cloned splice variants, and
although they could be detected in both compartments, we
observed a tendency toward nuclear enrichment similar to the
well-characterized HOTAIR lincRNA (Figure 3c). In summary,
these ﬁndings conﬁrm that metastatic melanoma cells express
several CASC15 splice variants originating from an alternative
TSS and predominantly localized in the cell nucleus. These
data were also useful for the accurate detection and silencing
of CASC15 transcripts in subsequent clinicopathological and
functional analyses.
CASC15 levels increase during melanoma progression
We next examined tissue expression levels of CASC15
transcripts. Using RT-qPCR, we assessed the levels of both
L Lessard et al.
CASC15 LincRNA in Melanoma
www.jidonline.org 2467
exon 8- and exon 10–11-containing isoforms in 70 formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissue samples. As for
metastatic melanoma cell lines, we found a positive correla-
tion between the levels of both isoform groups (Supple-
mentary Figure S7a online). With regard to melanoma
progression, CASC15 expression was signiﬁcantly increased
in advanced stage IV melanomas (brain and lung metastases)
relative to normal skin and nevus specimens (T-test; Po0.01;
Figure 4e and Supplementary Figure S7b online).
To better characterize in situ expression levels and
subcellular distribution of CASC15 transcripts, we performed
RNA in situ hybridization on 62 FFPE specimens using the
RNAscope technology as shown in Figure 4a–d (Wang et al.,
2012). The target sequence, covering CASC15 exons 5 to 12,
was designed for optimal sensitivity and to detect a maximum
number of expressed isoforms. In general, CASC15 RNA
detection was restricted to melanoma cells and absent from
other nonmelanoma cell types, except for rare lymphocyte
positivity. Most positive cells expressed 1 to 10 CASC15
copies, but 410 copies were also observed in 1–10% of
melanoma cells in different tumors (Figure 4d and g).
Consistent with our RT-qPCR cell line results (Figure 3c),
CASC15 RNA was principally located in the nucleus of
melanoma cells, but was also detected in the cytoplasm
(Figure 4a–d). Most importantly, we noticed signiﬁcant
differential expression of CASC15 during melanoma progres-
sion (Kruskal–Wallis test, Po0.01; Figure 4f). In particular, we
observed higher CASC15 levels in stage III lymph node (LN)
metastases relative to nonmalignant specimens (Mann–
Whitney test; Po0.01), as well as increased CASC15 levels
in stage IV brain and lung lesions relative to stage III LN
metastases (Mann–Whitney test; Po0.05; Figure 4f). Collec-
tively, these ﬁndings align with the results of our xenograft
mouse model of brain metastasis and further support a role for
CASC15 in melanoma progression from early stages to stage
IV metastasis.
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Figure 4. CASC15 (cancer susceptibility candidate 15) expression in melanoma specimens. (a–d) Representative CASC15 RNA in situ hybridization (RNA-ISH)
staining of archived melanoma specimens. (a) Primary melanoma with ≤1 copy/cell, (b) primary melanoma with 1–3 copies/cell, (c) melanoma lymph node
metastasis (LN mets) showing positive staining in melanoma cells and negative staining in lymphocytes, and (d) melanoma brain metastasis (Brain mets) showing
strong staining (44 copies/cell) in 430% of tumor cells. Scale bars =50 μm (panels) and 300 μm (inserts). (e) Reverse transcription and quantitative PCR (RT-
qPCR) detection of CASC15 expression levels (exon 8–containing isoforms) as a function of tumor stage. See Supplementary Table S1 online for details (LOG2 (n
+1) of 2− (ddCq) relative values; T-test; *Po0.05; **Po0.01; mean± SEM). (f) RNA-ISH detection of CASC15 expression levels (exons 5–12) as a function of tumor
stage (% positive cells; Mann–Whitney test; *Po0.05; **Po0.01, mean± SEM). (g) Same as in f, organized according to the number of copies per cell (average %
of cells per category for each sample group). (h) Kaplan–Meier curves representing the relationship between CASC15 expression in stage III melanoma LN mets
and 10-year disease-free survival (DFS). High: 475th percentile. Low: r75th percentile.
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CASC15 expression in melanoma LN metastases is an
independent predictor of disease recurrence and survival
We then sought to determine whether CASC15 expression,
which also displayed substantial interpatient variability
(Figure 4e and f), could be used to stratify patients at low
and high risk of metastatic melanoma progression to stage IV
melanoma. We performed RNA in situ hybridization as
described above on a tissue microarray containing 141 FFPE
LN metastasis specimens. Again, we noticed strong inter-
patient variability and a mean frequency of CASC15-positive
melanoma cells per LN metastasis (mean: 23%; % coefﬁcient
of variation: 103%) similar to our ﬁndings in the ﬁrst cohort
(mean: 18%; % coefﬁcient of variation: 129%; Figure 4f).
Subsequent Kaplan–Meier analysis of disease-free and overall
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Figure 5. CASC15 (cancer susceptibility candidate 15) is involved in melanoma cell transition between proliferative and invasive states. (a) Clonogenic
assays for WP, M16, and RKTJ-CB1 cell lines. Histograms depict the average colony number per condition for the respective cell line (T-test, *Po0.05, **Po0.01;
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melanoma cell lines. Red gradient: positive correlation. Blue gradient: negative correlation. Note the unequivocal inverse correlation between proliferative and
invasive signature genes. (d) Effect of siPool2-mediated CASC15 knockdown on the levels of 31 proliferative and 21 invasive signature genes (Supplementary
Table S8 online). Bars: SEM. Values below zero indicate downregulation, and values above 0 indicate upregulation relative to siCTRL (LOG2 value of fold
change).
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survival showed that patients with elevated CASC15 expres-
sion had signiﬁcantly shorter disease-free survival compared
with low-CASC15-expressing patients (Figure 4h and
Supplementary Figure S7c online). Moreover, in stepwise
multivariable Cox regression analyses, CASC15 expression
improved the predictive strength of multivariate models of
stage III melanoma outcome (disease-free survival: Po0.05;
overall survival: Po0.01) over clinical variable–only models
(Supplementary Table S6 online). Taken together, these
ﬁndings support the prognostic signiﬁcance of CASC15
expression in metastatic melanoma.
CASC15 silencing in melanoma cell lines induces a phenotype
switch
To characterize the function of CASC15 transcripts, we
performed RNA interference–mediated silencing using small
interfering RNA (siRNA) pools targeting most CASC15 iso-
forms identiﬁed in the RACE experiments. We ﬁrst assessed
CASC15 knockdown efﬁciency and selected three high-
CASC15-expressing cell lines (WP, M16, and RKTJ-CB1)
showing consistent reduction in all four isoform groups
examined (Supplementary Figure S8 online). With the
exception of siPool1-transfected RKTJ-BI3 cells, CASC15
silencing by both siRNA pools had an important inhibitory
effect on melanoma cell clonogenic growth (Figure 5a). The
inhibition was consistently more pronounced in siPool2
conditions (Figure 5a) and was always accompanied by a
signiﬁcant increase in melanoma cell invasiveness
(Figure 5b), a phenomenon reminiscent of melanoma cell
phenotype switching between proliferative and invasive
states. The underlying siPool2-induced alterations in cell-
cycle kinetics and baseline survival were cell type speciﬁc
(Supplementary Figure S9 online) and involved a decreased
rate in DNA synthesis (M16), a combination of decreased
DNA synthesis and increased cell death (RKTJ-BI3), or
increased DNA synthesis counterbalanced by increased cell
death (WP). Interestingly, the RKTJ-CB1 cells responded
differently to siPool1-mediated silencing, showing the reverse
pattern: an increased clonogenic growth and a decline in
invasive properties (Figure 5a and b). Consistently, this effect
was associated with a modest but signiﬁcant increase in the
rate of DNA synthesis (Supplementary Figure S9a online).
To gather additional evidence for a role of CASC15 in
phenotype switching, we performed expression arrays to
assess whether variations of CASC15 levels (exons 5–12) in
metastatic melanoma cell lines (n= 47) could discriminate
between the previously reported proliferative (motif 1) and
invasive (motif 2) melanoma gene signatures associated with
this process (Hoek et al., 2006; Stanisz et al., 2014). As
expected, the two signatures were inversely correlated
(Figure 5c and Supplementary Table S7 online), thus
validating published ﬁndings (Hoek et al., 2006).
Interestingly, we found that CASC15 expression was both
positively correlated with a large subset of proliferative genes
and inversely correlated with several invasion-related genes
(Figure 5c and Supplementary Table S7 online). Most
importantly, RNA sequencing of siPool2-mediated CASC15
knockdown in all three cell lines identiﬁed a downregulation
of 31 proliferative signature genes, including the master
regulator transcription factors MITF and SOX10, and a
concomitant upregulation of 21 invasive signature genes
(Figure 5d and Supplementary Table S8 online). Overall, these
results underscore the functional complexity of CASC15
transcripts and position CASC15 transcripts as candidate
regulators of melanoma phenotype switching.
DISCUSSION
In recent years, lncRNAs have emerged as important
regulators of cellular homeostasis and cell fate (Kung et al.,
2013; Flynn and Chang, 2014), whereby the number of
lncRNAs implicated in tumorigenesis and other diseases is
growing rapidly (Gutschner and Diederichs, 2012). In
melanoma, only a limited number have been identiﬁed and
functionally investigated (Khaitan et al., 2011; Flockhart et al.,
2012; Tang et al., 2013; Wu et al., 2013; Aftab et al., 2014;
Tian et al., 2014). For instance, the intronic lncRNA SPRY4-
IT1 has been identiﬁed as a melanoma upregulated transcript
with antiapoptotic and proinvasive functions (Khaitan et al.,
2011; Mazar et al., 2014), and the lincRNA BANCR has been
characterized as a BRAFmt-regulated transcript involved in
melanoma cell migration (Flockhart et al., 2012). In this study,
we sought to expand upon the literature of melanoma-
associated lncRNAs by analyzing CNAs of nonprotein-coding
intergenic domains in metastatic melanoma. Our screening
uncovered a large number of frequently altered putative
lincRNA domains. We noticed a particularly high concentra-
tion of gained intergenic domains on chromosome 6p,
suggesting that this chromosome arm may be a possible hot
spot for tumor-promoting lincRNAs that warrants further
investigation. Although we acknowledge that the number of
currently annotated lincRNA genes (or transcriptional units)
largely exceeds the number of analyzed intergenic domains,
our strategy was nonetheless successful in identifying a
clinically and functionally relevant lincRNA locus and
justiﬁes the pursuit of more comprehensive genome-wide
integrative studies.
The CASC15 locus was originally identiﬁed in silico as a
highly active, nonprotein-coding transcriptional unit with
several associated ESTs and mRNAs (Glusman et al., 2006).
Subsequently, an independent genome-wide association
study reported that three intronic single-nucleotide poly-
morphisms (SNPs) within the CASC15 locus (between exons 9
and 10) were strongly associated with clinically aggressive
neuroblastoma (Maris et al., 2008). More recently, one of
these SNPs has been linked to CASC14 expression levels (also
known as NBAT-1) that were shown to have a pivotal role in
neuroblastoma progression (Pandey et al., 2014). Our results
revealed a similar association with aggressive tumors, linking
the CASC15 locus and related transcripts to metastatic
melanoma progression. Whether the high-risk SNPs identiﬁed
in neuroblastoma are also associated with aggressive mela-
nomas remains to be tested, but like other lncRNAs such
as ANRIL (Burd et al., 2010) and CCAT2 (Ling et al., 2013)
they may affect the splicing and/or expression of CASC15
transcripts.
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RACE analyses conﬁrmed that melanoma lines express a
remarkable variety of alternatively spliced CASC15 isoforms
and exon variants. An even greater number may be present in
melanoma cells as our RACE experiments only focused on
exon 8–containing transcripts that were conserved between
RefSeq (release 59) and GENCODE v17 annotations, as well
as several ESTs. This splice variant complexity has been
observed for other well-characterized lncRNAs such as ANRIL
(Burd et al., 2010), MEG3 (Zhang et al., 2010), and CRNDE
(Ellis et al., 2012), and has been proposed to confer variant-
speciﬁc structural properties affecting their function. With
regard to CASC15 isoforms, alternative splicing may dictate
their subcellular distribution: despite overall nuclear enrich-
ment of CASC15 transcripts, the nuclear/cytoplasmic ratio of
exon 8–containing isoforms was consistently higher than
isoforms containing exons 10–11 and 11–12, a pattern that
may reﬂect variable functions. Some of the linear isoforms
detected in our RACE experiments could also be by-products
of circular RNA (circRNA) genesis, a likely possibility given
the reported existence of a highly expressed 204-nucleotide
circRNA isoform emanating from the CASC15 locus (Salzman
et al., 2013). In addition to splice variants, we found that
melanoma cells preferentially express transcripts from an
alternative TSS that may also be important for CASC15
isoform function. Dissecting out the roles of individual
CASC15 isoforms will be a challenging task, but the locus
nonetheless represents an exquisite model to study the
transcriptional regulatory mechanisms controlling lncRNA
biogenesis.
Although CASC15 isoforms may exert speciﬁc functions,
our ﬁndings demonstrate that their global upregulation is
associated with melanoma progression to advance stages of
distant metastasis. Moreover, CASC15 levels can be used to
discriminate between patients at low and high risk of disease
progression. The ability of CASC15 expression levels to
predict AJCC stage III melanoma recurrence is important given
the pressing need for biomarkers predictive of melanoma
progression to stage IV disease (Eggermont et al., 2014). To fully
exploit the potential of targeted therapies, stage IV melanoma
needs to be diagnosed earlier for prompt treatment, ideally
before evidence of widespread dissemination. In this context,
CASC15 merits further independent validation to conﬁrm its
prognostic utility in melanoma patients.
To our knowledge, CASC15 knockdown experiments
uncovered a previously unreported role for lncRNAs in the
regulation of melanoma cell transition between proliferative
and invasive states. Inherent to phenotype switching is the
stem cell–like plasticity of melanoma cells (Hoek and Goding,
2010), a property in line with the well-recognized involve-
ment of lncRNAs in the regulation of pluripotency and
differentiation (Hu et al., 2012; Flynn and Chang, 2014).
LncRNAs have been shown to be critical for embryonic stem
cell maintenance/differentiation (e.g., RNCR2, Xist), induced
pluripotent stem cell reprograming (e.g., linc-ROR), neural
progenitor differentiation (e.g., lncRNA_N1-3; RMST), and
adult somatic progenitor cell maintenance (e.g., ANCR). The
regulation of phenotype switching by CASC15 adds to these
lncRNA-mediated stem cell–like functions and provides the
grounds for future studies addressing the contribution of
CASC15 transcripts to melanoma initiating/stem cell main-
tenance. In particular, it would be interesting to assess
whether CASC15 transcripts directly regulate the master
melanoma oncogene MITF and/or its upstream inducer
SOX10, given their known implication in melanocyte stem
cell fate and phenotype switching (Hoek and Goding, 2010),
and their downregulation upon CASC15 knockdown
(Figure 5d and Supplementary Table S8 online).
The silencing of CASC15 transcripts had a marked impact
on melanoma cell phenotype. Moreover, especially in RKTJ-
CB1 cells, our ﬁndings suggest that CASC15-targeting siRNAs
can exert opposite effects despite similar knockdown efﬁ-
ciencies (Supplementary Figure S8 online). Although some
isoforms not covered by our RT-qPCR assays could be
differentially silenced, another likely explanation could reside
in the sequences targeted by the two siRNA pools, some of
which may be critical for CASC15 function(s). For instance,
speciﬁc sequences may interact with RNA/DNA or proteins
and/or may encode small functional peptides involved in the
regulation of proliferative or invasive states (Bazzini et al.,
2014).
In summary, analysis of altered intergenic domains in
metastatic melanoma uncovered the CASC15 locus as a
frequently gained region with tumor-promoting properties.
CASC15 lincRNA isoforms are associated with melanoma
progression and disease recurrence and have a key role in
melanoma phenotype switching. Our study represents a
largely unexplored area of melanoma molecular biology
and support the functional relevance of lincRNAs in
melanoma progression.
MATERIALS AND METHODS
Melanoma specimens and cell lines
Frozen and FFPE tissues were obtained under an institutional review
board (IRB) protocol that was approved by the Saint John’s Health
Center/John Wayne Cancer Institute joint IRB and Western IRB.
Written informed consent was obtained for all subjects. Melanoma
cell lines and immortalized pMEL-NRAS(G12D) melanocytes (gift
from Dr Levi Garraway, Broad Institute, Cambridge, MA) were
cultured in RPMI-1640 medium as already described (Marzese et al.,
2014a). Primary human melanocytes (Life Technologies, Carlsbad,
CA) were cultured in Medium 254 supplemented with human
melanocyte growth supplement-2, PMA-Free (HMGS-2). See
Supplementary Materials and Methods online for more details.
Nucleic acid extraction and BRAF sequencing
DNA from frozen tissues and cell lines was extracted using the
QiAmp DNA mini kit (Qiagen, Valencia, CA) and quantiﬁed with the
Quant-iT PicoGreen double-stranded DNA Kit (Life Technologies).
Direct sequencing (Euroﬁns, Hunstville, AL) was used for the
assessment of BRAF mutational status as previously reported
(Marzese et al., 2014b). Total RNA was extracted from cell lines
using TriReagent (Molecular Research Center, Cincinnati, OH) and
from FFPE tissues using RNA-Solv Reagent (Omega Bio-Tek,
Norcross, GA) according to the manufacturers’ instructions. Isolation
of nuclear and cytoplasmic RNA was performed using the PARIS Kit
(Life Technologies). RNA concentration was quantiﬁed and qualiﬁed
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by UV absorption spectrophotometry and the Quant-iT RiboGreen
RNA Assay Kit (Life Technologies).
DNA copy number proﬁling
Genotyping of DNA from melanoma specimens (n= 78,
Supplementary Table S1 online) was performed using the Affymetrix
Genome-Wide SNP 6.0 array and analyzed using Genotyping
Console 4.0 (Affymetrix, Santa Clara, CA) as previously described
(Marzese et al., 2014a). More details are provided in the Supple-
mentary Materials and Methods section online.
Reverse transcription and quantitative real-time PCR
RT of total RNA was performed as previously described (Marzese
et al., 2014a). Before RT, we performed DNase treatment on all the
samples using the TURBO DNA-free Kit according to the manufac-
turer’s instructions (Life Technologies). The CFX96 Real-Time PCR
Detection System (Bio-Rad Laboratories, Hercules, CA) was used for
qPCR ampliﬁcation. Refer to Supplementary Materials and Methods
online for more details.
Rapid ampliﬁcation of cDNA ends
The FirstChoice RLM-RACE Kit (Life Technologies) was used for
5′- and 3′-RACE identiﬁcation of CASC15 isoforms. CASC15 exon
8–speciﬁc outer and inner primers are listed in Supplementary
Table S9 online. See Supplementary Materials and Methods online
for more details.
RNA in situ hybridization
The RNAscope RNA in situ hybridization protocol was performed as
previously described (Wang et al., 2012). RNA quality control
(human ubiquitin C gene) and negative control (bacterial dapB gene)
probes were used on each FFPE specimen. Scoring was performed by
two independent investigators (LL and HW) who examined whole
tumor sections (or tissue microarray cores) for CASC15 staining. The
RNAscope Fluorescent Assay was also used as previously described
(Wang et al., 2012) on M16 and WP cell lines to assess the speciﬁcity
of CASC15 probes (Supplementary Figure S10 online).
Clonogenic growth and invasion assays
For clonogenic assays, cells were plated in 6-well plates 24 h
following siRNA transfection at a density of 5,000 (WP), 2,000 (M16),
and 1,000 (RKTJ-CB1) cells per well. Medium was refreshed the next
day and changed every 3 days until colonies reached a size of ~ 50
cells (10–13 days after plating). Colonies were then ﬁxed in 0.5%
crystal violet in methanol. Images of each well were captured using
MyECL imager (Thermo Scientiﬁc, Waltham, MA), and the colony
number was quantiﬁed using the Image J software (Bethesda, MD)
with a particle size threshold of ≥ 4 pixels for colonies ≥ 50 cells.
Melanoma cell invasion was assessed using a transwell matrigel
chamber system following the manufacturer’s instructions (BD
Biosciences, San Diego, CA). See Supplementary Materials and
Methods online for more details.
Genome-wide gene expression proﬁling
Genome-wide exon array gene expression proﬁling in melanoma cell
lines (n= 47, Supplementary Table S1 online and Figure 5c) was
performed as already described (Marzese et al., 2014a). For CASC15,
probes targeting exons 5 to 12 (RefSeq annotation) were used to
determine overall CASC15 expression levels. For total RNA
sequencing (Figure 5d), details are provided in the Supplementary
Materials and Methods section online.
Statistics
Statistical analyses were performed using the Prism 5.0 GraphPad
Software (La Jolla, CA) and the JMP 8 statistical package (SAS
Institute, Cary, NC). A detailed description of all statistical tests is
provided in the Supplementary Materials and Methods section
online.
Data access
Copy number and exon array gene expression data have been
deposited in Gene Expression Omnibus under the accession numbers
GSE44019 and GSE44660, respectively.
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